Related Experiment Video

Updated: Jul 3, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

PIM3 Kinase: A Promising Novel Target in Solid Cancers

Pinar Atalay1, Bulent Ozpolat1,2

  • 1Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.

Cancers
|February 10, 2024
PubMed

Insights

Provirus-integrating Moloney site 3 (PIM3) kinase is a proto-oncogene overexpressed in many cancers. Inhibiting PIM3 shows promise for suppressing tumor growth and metastasis, highlighting its potential as a cancer therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Provirus-integrating Moloney site 3 (PIM3) is a serine/threonine kinase and proto-oncogene.
  • PIM3 is frequently overexpressed in cancers from endoderm-derived tissues, including liver, pancreas, colon, stomach, prostate, and breast.
  • Overexpressed PIM3 drives cancer cell proliferation, survival, invasion, tumor growth, metastasis, and therapy resistance.

Purpose of the Study:

  • To review recent developments on the role of PIM3 in various cancers.
  • To explore the potential of PIM3 as a novel molecular target for cancer therapy.
  • To discuss the current status of PIM-targeted therapies in clinical trials.

Main Methods:

  • Literature review of recent studies on PIM3 function and targeted therapies.
  • Analysis of PIM3's role in oncogenic signaling pathways.
  • Examination of preclinical data on genetic inhibition of PIM3.

Main Results:

  • Genetic inhibition of PIM3 suppressed in vitro proliferation and in vivo tumor growth and metastasis in preclinical models.
  • PIM3 activation promotes cancer progression and resistance to chemotherapy and radiation.
  • PIM3 contributes to an immunosuppressive tumor microenvironment.

Conclusions:

  • PIM3 is a critical oncogene with significant potential as a therapeutic target in solid tumors.
  • While pan-PIM inhibitors are in early clinical trials for hematological cancers, no FDA-approved inhibitors currently exist for PIM3-targeted therapy.
  • Further research and clinical development are warranted to leverage PIM3 inhibition for cancer treatment.
Keywords:
PIM kinase inhibitorsPIM3serine/threonine kinasesolid cancertargeted therapiestriple-negative breast cancer

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

9.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K